OppenheimerFunds’s Blueprint Medicines BPMC Stock Holding History

OppenheimerFunds’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$137M	Buy	1,710,895 +5,720	+0.3%	+$423K	0.17%	134
2018 Q4	$91.9M	Buy	1,705,175 +36,394	+2%	+$2.21M	0.13%	155
2018 Q3	$130M	Sell	1,668,781 -8,950	-0.5%	-$622K	0.15%	158
2018 Q2	$107M	Buy	1,677,731 +64,095	+4%	+$5.1M	0.13%	178
2018 Q1	$148M	Sell	1,613,636 -18,370	-1%	-$1.58M	0.18%	135
2017 Q4	$123M	Buy	1,632,006 +126,752	+8%	+$8.92M	0.15%	162
2017 Q3	$105M	Sell	1,505,254 -19,748	-1%	-$1.06M	0.13%	183
2017 Q2	$77.3M	Buy	1,525,002 +879,605	+136%	+$37.3M	0.1%	224
2017 Q1	$25.8M	Buy	+645,397	New	+$23.1M	0.03%	501

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OppenheimerFunds's BPMC Position: Q1 2019 in Review

OppenheimerFunds increased its Blueprint Medicines (BPMC) stake by 0.34% in Q1 2019, buying an estimated $423K and bringing the position to 1,710,895 shares worth $137M. The position accounts for 0.17% of the portfolio, ranked #134.

OppenheimerFunds first reported a position in BPMC in Q1 2017 and has held it in 9 quarters since. The position peaked at $148M in Q1 2018. 203 funds tracked by Wall St. Rank hold BPMC as of Q1 2019.

OppenheimerFunds held 1,710,895 shares of Blueprint Medicines worth $137M as of Q1 2019.
OppenheimerFunds bought 5,720 Blueprint Medicines shares in Q1 2019, an estimated $423K.
Blueprint Medicines made up 0.17% of OppenheimerFunds's portfolio in Q1 2019, its #134 holding.
OppenheimerFunds first reported a position in Blueprint Medicines in Q1 2017 and has held it in 9 quarters since.
OppenheimerFunds's Blueprint Medicines position peaked at $148M in Q1 2018.
203 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.